Format

Send to

Choose Destination
Vet Clin North Am Equine Pract. 2017 Apr;33(1):127-139. doi: 10.1016/j.cveq.2016.11.003. Epub 2017 Feb 9.

Therapeutics for Equine Endocrine Disorders.

Author information

1
Liphook Equine Hospital, Liphook, Hampshire GU30 7JG, UK. Electronic address: andy.durham@theleh.co.uk.

Abstract

Equine endocrine disease is commonly encountered by equine practitioners. Pituitary pars intermedia dysfunction (PPID) and equine metabolic syndrome (EMS) predominate. The most logical therapeutic approach in PPID uses dopamine agonists; pergolide mesylate is the most common. Bromocryptine and cabergoline are alternative drugs with similar actions. Drugs from other classes have a poor evidence basis, although cyproheptadine and trilostane might be considered. EMS requires management changes as the primary approach; reasonable justification for use of drugs such as levothyroxine and metformin may apply. Therapeutic options exist in rare cases of diabetes mellitus, diabetes insipidus, hyperthyroidism, and critical illness-related corticosteroid insufficiency.

KEYWORDS:

Diabetes; EMS; Endocrine; Equine; PPID; Therapeutics

PMID:
28190613
DOI:
10.1016/j.cveq.2016.11.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center